DIRS.INFO The most relevant business & tech news

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ We're selling shares in this outperforming drugmaker and locking in a huge gain
▼ + stars: | 2023-09-12 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Shortly after the opening bell, we will be selling 40 shares of Eli Lilly (LLY) at roughly $596. In a sector that has been a poor performer this year, Eli Lilly has been the star of the show. Quarter to date, Eli Lilly shares have rallied about 27%, while the sector's performance is flat. LLY YTD mountain Eli Lilly YTD performance The enthusiasm for Eli Lilly up to this point has been justified. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Eli Lilly, Jim Cramer's, Eli Lilly YTD, Jim Cramer, Jim, Frederick Florin Organizations: CNBC, AFP, Getty Locations: Fegersheim, France

☆ Here's our internal debate about what to do with stocks making all-time highs
▼ + stars: | 2023-06-16 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

All of the following stocks hit all-time price highs Friday, except for Meta Platforms (META), which was a multiyear high. Apple P/E next 12 months (NTM) ratio: 29x 5 year Average P/E (NTM): 22.7x PEG (NTM) ratio: 2.9x 5 year average PEG (NTM) Ratio: 1.9x Apple 's (AAPL) valuation has gotten stretched in recent weeks, even when factoring in growth expectations. Meta Platforms P/E (NTM) ratio: 21.4x 5 year Average P/E (NTM): 21.2x PEG (NTM) ratio: 1.6x 5 year average PEG (NTM) Ratio: 2.2x Meta has been on an incredible run. Microsoft P/E (NTM) ratio: 31.7x 5 year Average P/E (NTM): 27.7x PEG (NTM) ratio: 2.5x 5 year average PEG (NTM) ratio: 2.1x Microsoft's run has seen its earnings-based valuation (P/E) expand, even when adjusting for growth (PEG). NVDA YTD mountain Nvidia YTD performance Nvidia has a history of beating estimates and ending up cheaper in hindsight.

Persons: Jim Cramer, Jim, we've, Rather, Eli Lilly P, Eli Lilly's, Eli Lilly YTD, Lilly, we're, Eli Lilly, Jim Cramer's, Michael Nagle Organizations: Nasdaq, Nvidia, Meta, Apple, UBS, Credit Suisse, Mounjaro, Microsoft, Palo Alto Networks, CNBC, Bloomberg, Getty Locations: —, Palo

We are selling 50 shares of Eli Lilly (LLY) at roughly $442 each. Following Monday's trade, Jim Cramer's Charitable Trust will own 150 shares of LLY, decreasing its weighting in the portfolio to about 2.5% from 3.33%. We're taking some Eli Lilly off the table Monday afternoon on the stock's breakout to another new all-time high. The FDA in early January granted accelerated approval to a drug similar to donanemab, which was developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB). Like Pfizer's drug, Lilly is working on an oral type-2 diabetes and chronic weight management drug called orforglipron, which could be similar to the Mounjaro injectable.

☆ We're making five price target changes and one rating upgrade after a crazy week of earnings
▼ + stars: | 2023-05-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

AAPL YTD mountain Apple YTD performance Apple (AAPL): We're raising our price target to $185 per share from $175 in response to the strong quarter Thursday evening. LLY YTD mountain Eli Lilly YTD performance Eli Lilly (LLY): We're increasing our price target on Eli Lilly again, this time to $460 per share from $430. Our new price target is in reaction to the positive Alzheimer's drug trial data that was much better than what we expected. HAL YTD mountain Halliburton YTD performance Halliburton (HAL): We are lowering our price target on this North American-focused oil services giant to $40 per share from $48. SBUX YTD mountain Starbucks YTD performance Starbucks (SBUX): We're bumping up our price target to $125 per share from $120 and upgrading our rating to a 1 following the stock's pullback in reaction to the recent earnings result .

PANW YTD mountain Palo Alto Networks YTD About half of the funds raised from this Lilly sale will go into building up our position in Palo Alto Networks . But here is our problem with reading too much into the conference calls of Tenable and Cloudfare and extrapolating that to Palo Alto. While it is highly likely that deal uncertainty increased out of the regional banking crisis, Palo Alto Networks is in a special class within the industry because it is taking share from the little guys. As a market leader in thirteen categories within security, Palo Alto is a winner from what is happening in the market. And with a management team committed to profitable growth and accelerating leverage in the business, we think Palo Alto Networks will continue to surprise to the upside.

Search resuls for: "Eli Lilly YTD"

6 mentions found